Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD

Choosing a safe disease modifying therapy during the COVID-19 pandemic is challenging. This case series study was conducted to determine the incidence rate and the course of Covid-19 infection in MS/NMOSD pati...

Source: BMC Neurology - May 1, 2021 Category: Neurology Authors: Sara Esmaeili, Mohammad Hossein Abbasi, Meysam Abolmaali, Mohammad Mojtahed, Seyedeh Niloufar Rafiei Alavi, Sevim Soleimani, Mahisa Mokhtari, Jaber Hatam, Samaneh Tanhapour Khotbehsara, Mohammad Reza Motamed, Mohammad Taghi Joghataei, Zahra Mirzaasgari an Tags: Research Source Type: research